Cite
HARVARD Citation
Stone, J. et al. (n.d.). FRI0588 Interim results of a phase 2 study of XMAB®5871, a reversible B cell inhibitor, in IGG4-related disease. Annals of the rheumatic diseases. pp. 711-712. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Stone, J. et al. (n.d.). FRI0588 Interim results of a phase 2 study of XMAB®5871, a reversible B cell inhibitor, in IGG4-related disease. Annals of the rheumatic diseases. pp. 711-712. [Online].